- Home
- INBS vs BCAB Comparison
INBS vs BCAB Comparison
Compare INBS & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INBS | BCAB |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7M | 6.4M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | INBS | BCAB |
|---|---|---|
| Price | $2.55 | $4.00 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 172.8K | 29.6K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 68.65 | 29.86 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,980,484.00 | $300,000.00 |
| Revenue This Year | $778.48 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.54 | $0.12 |
| 52 Week High | $24.90 | $6.52 |
Technical Indicators
Market Signals| Indicator | INBS | BCAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.69 | 49.49 |
| Support Level | $2.33 | $3.92 |
| Resistance Level | $3.16 | $6.33 |
| Average True Range (ATR) | 0.52 | 0.44 |
| MACD | -0.07 | -0.10 |
| Stochastic Oscillator | 6.78 | 42.50 |
Price Performance
Historical ComparisonAbout INBS Intelligent Bio Solutions Inc.
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs. The company's operations are organized on a single reportable segment, which includes all activities related to the discovery, development, and commercialization of its CAB products.